Topline data from REDEFINE 1 found CagriSema, a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, achieved superior weight loss versus placebo in adults with obesity or overweight
In the Phase 2 fatty-liver subgroup, liver fat fell by half at the bottom dose and by most at the top. Those figures describe the studied cohorts, and the Phase 3 weight result remains company-reported
No evidence in decades of studies
When you should be especially cautious There are several contexts where caution should increase
Foundational work from the de Keizer laboratory (Baar et al., Cell, 2017) reported that the peptide perturbs the FOXO4-p53 association, leading to p53 nuclear exclusion and apoptosis that appeared preferential to senescent cells in cultured cells and aged mouse models
MIC injections cannot address serious weight issues or obesity